Tislelizumab Plus Chemo Sustains Survival Benefit at 3 Years in Metastatic NPC - OncLive

अप्रैल 8, 2026 Last updated : अप्रैल 8, 2026 health.aiweekly.co.in

Tislelizumab Plus Chemo Sustains Survival Benefit at 3 Years in Metastatic NPC  OncLive

श्रेणी
Uncategorized
Previous article
Genetic predictors of GLP1 receptor agonist weight loss and side effects - Nature
अप्रैल 8, 2026
Next article
Measles outbreak spreads in Utah, hitting people without the vaccine - KUER
अप्रैल 8, 2026